title: Expression of selected regulatory molecules on the CD83+ monocyte-derived dendritic cells generated from patients with laryngeal cancer and their clinical significance.
abstract: B7H1 and B7H4 overexpression is associated with inhibition of the immune system in many solid tumors, and altogether with CD200 molecule plays an important role in tumor invasion by promoting malignant transformation. However, there is no report about impact of these molecules on laryngeal squamous cell carcinoma. The objective of the present study was to assess by means of flow cytometry the expression of B7H1, B7H4, CD200, and CD200R on CD83+ monocyte-derived dendritic cells (Mo-DC), pulsed with autologous tumor cell lysates (aTCL) in patients who suffer from G1, G2, or G3 laryngeal carcinoma (LC, n = 60) in comparison to healthy donors (HD, n = 15). It has been demonstrated that median value of the percentages of CD83+ B7H1+, CD83+ B7H4+, and CD83+ CD200+ cells were higher in LC patients than HD (p = 0.041, p ≤ 0.0001, and p = 0.02, respectively). Mean fluorescence intensity (MFI) of CD200, CD200R, B7H1, and B7H4 on the Mo-DC pulsed with aTCL of the patients was also higher than on the Mo-DC of HD (p ≤ 0.0001, p ≤ 0.0001, p = 0.002, and p ≤ 0.0001, respectively). The highest MFI levels of all molecules were noted in grade 3 LC. The aforementioned results prove that there is a relation between the presence of laryngeal cancer and the expression of B7H1, B7H4, CD200, and CD200R regulatory molecules on the CD83+ Mo-DC pulsed with autologous cancer cell lysates. Strong association of LC grade and the tested antigens expression suggests a critical role for these proteins in LC biology.
authors: Department of Otolaryngology and Laryngeal Oncology, Medical University of Lublin, Jaczewskiego 8 Street, 20-954 Lublin, Poland.
authors: Janusz
authors: J
authors: Klatka
authors: Ewelina
authors: E
authors: Grywalska
authors: Maria
authors: M
authors: Klatka
authors: Magdalena
authors: M
authors: Wasiak
authors: Adrian
authors: A
authors: Andrzejczak
authors: Jacek
authors: J
authors: Rolinski
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism; D000954:Antigens, Surface / Q000378:metabolism; D060890:B7-H1 Antigen / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000276:immunology / Q000378:metabolism*; D016022:Case-Control Studies; D003713:Dendritic Cells / Q000378:metabolism*; D005434:Flow Cytometry; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism; D007822:Laryngeal Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000378:metabolism*; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism; D008875:Middle Aged; D009000:Monocytes / Q000378:metabolism*; D064446:Orexin Receptors; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000378:metabolism; D019139:Tumor Escape / Q000276:immunology; D060907:V-Set Domain-Containing T-Cell Activation Inhibitor 1 / Q000378:metabolism; D000097802:CD83 Antigen
chemical_list: D015703:Antigens, CD; D000954:Antigens, Surface; D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; D007136:Immunoglobulins; D008562:Membrane Glycoproteins; D064446:Orexin Receptors; D011956:Receptors, Cell Surface; D060907:V-Set Domain-Containing T-Cell Activation Inhibitor 1; D000097802:CD83 Antigen; C477337:CD200R1 protein, human; C423236:CD274 protein, human; C042739:antigens, CD200
references: Science. 2000 Dec 1;290(5497):1768-71
references: 11099416
references: Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):931-6
references: 11792864
references: Immunity. 2000 Aug;13(2):233-42
references: 10981966
references: Eur Arch Otorhinolaryngol. 2012 Sep;269(9):2091-6
references: 22539095
references: J Immunol. 1997 May 15;158(10):4548-54
references: 9144466
references: Cancer Res. 2010 Apr 1;70(7):2962-72
references: 20332223
references: Eur Arch Otorhinolaryngol. 2012 Sep;269(9):2103-9
references: 22186766
references: J Immunol. 2005 Aug 1;175(3):1586-92
references: 16034097
references: Front Immunol. 2011 Sep 27;2:39
references: 22566829
references: Cancer Immunol Immunother. 2006 Feb;55(2):151-9
references: 15889251
references: J Immunol. 2007 May 1;178(9):5595-605
references: 17442942
references: Eur Arch Otorhinolaryngol. 2013 Mar;270(3):1009-17
references: 23179937
references: Onkologie. 2012;35(11):700-5
references: 23147549
references: Biochem Soc Symp. 1986;51:149-57
references: 2880589
references: Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1041-6
references: 16418292
references: J Immunol. 2008 Jan 15;180(2):699-705
references: 18178807
references: Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9482-7
references: 9689106
references: Eur J Med Res. 2011 Jul 25;16(7):295-302
references: 21813370
references: J Immunol. 2010 May 15;184(10):5466-5474
references: 20375308
references: J Leukoc Biol. 2006 Apr;79(4):686-95
references: 16461745
references: J Leukoc Biol. 2010 Aug;88(2):361-72
references: 20442224
references: Front Biosci. 2005 Sep 01;10:2856-60
references: 15970540
references: Int Immunopharmacol. 2011 Jul;11(7):794-801
references: 21281752
references: Blood. 2004 Apr 1;103(7):2691-8
references: 14644999
references: Adv Exp Med Biol. 2013;785:67-75
references: 23456839
references: Int J Immunopharmacol. 1997 Nov-Dec;19(11-12):629-44
references: 9669203
references: J Immunol. 2004 Jun 15;172(12):7744-9
references: 15187158
references: Immunology. 2001 Feb;102(2):173-9
references: 11260322
references: J Immunol. 1999 Jan 15;162(2):774-81
references: 9916698